Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 15;134(22):e183354.
doi: 10.1172/JCI183354.

Xylazine induces dopamine release and augments the effects of fentanyl

Affiliations

Xylazine induces dopamine release and augments the effects of fentanyl

Joseph R Trinko et al. J Clin Invest. .
No abstract available

Keywords: Addiction; Neuroscience.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors have declared that no conflict of interest exists.

Figures

Figure 1
Figure 1. Xylazine induces dopamine release through an α2 adrenergic receptor effect and potentiates the neurochemical effects of fentanyl.
(A) Xylazine (red arrow) significantly induced dopamine release (n = 6/group; repeated measures [RM] 1-way ANOVA main effect of time F(44,220) = 4.499, ****P < 0.0001) and (B) reduced locomotor activity (n = 6/group; RM 1-way ANOVA main effect of time F(44,220) = 3.452, ****P < 0.0001). (C) Pretreatment with the α2 adrenergic receptor antagonist atipamezole (red arrow) significantly blocked the effects of xylazine (blue arrow) on dopamine release (n = 6/group; 2-way RM-ANOVA main effect of treatment F(1, 10) = 21.79, ***P = 0.0009; treatment × time interaction F(34, 340) = 12.19, ****P < 0.0001 analyzing 70 minutes after atipamezole and xylazine treatments). (D) Atipamezole partially attenuated the effects on locomotor activity (n = 6/group; 2-way RM-ANOVA main effect of treatment F(1,10) = 18.60, **P = 0.0015; treatment × time interaction F(34,340) = 1.872, **P = 0.0030). (E) Fentanyl treatment (red arrow) induced significant dopamine release (n = 6/group; 1-way RM-ANOVA main effect of time F(44, 220) = 34.52, ****P < 0.0001) and locomotor activity (n = 6/group; RM 1-way ANOVA main effect of time F(44,220) = 1.828, **P = 0.0026) (F). (G) Coadministration of fentanyl and xylazine (red arrow) significantly augmented the effects of fentanyl alone on dopamine release (n = 6/group;2-way RM-ANOVA main effect of treatment F(1,10) = 14.01, **P = 0.0038, and a significant interaction of treatment × time F(44, 440) = 9.751, ****P < 0.0001), while locomotor activity was reduced compared to fentanyl alone (n = 4 combo, n = 6 fentanyl; 2-way RM-ANOVA main effect of treatment F(1,8) = 60.65, ****P < 0.0001; treatment × time interaction F(44,352) = 2.343, ****P < 0.0001) (H). All error bars are SEM.

References

    1. Thangada S, et al. Notes from the field: xylazine, a veterinary tranquilizer, identified as an emerging novel substance in drug overdose deaths - Connecticut, 2019-2020. MMWR Morb Mortal Wkly Rep. 2021;70(37):1303–1304. doi: 10.15585/mmwr.mm7037a5. - DOI - PMC - PubMed
    1. Gupta R, et al. Xylazine — medical and public health imperatives. New Engl J Med. 2023;388(24):2209–2212. doi: 10.1056/NEJMp2303120. - DOI - PubMed
    1. Rubin R. Here’s What to Know About Xylazine, aka Tranq, the Animal Tranquilizer Increasingly Found in Illicit Fentanyl Samples. JAMA. 2023;329(22):1904–1906. doi: 10.1001/jama.2023.8625. - DOI - PubMed
    1. Khatri SN, et al. Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats. Exp Clin Psychopharmacol. 2023;32(2):150–157. doi: 10.1037/pha0000670. - DOI - PMC - PubMed
    1. Park JW, et al. Noradrenergic modulation of dopamine transmission evoked by electrical stimulation of the locus coeruleus in the rat brain. ACS Chem Neurosci. 2017;8(9):1913–1924. doi: 10.1021/acschemneuro.7b00078. - DOI - PubMed